Editas Medicine's (EDIT) "Market Perform" Rating Reiterated at Oppenheimer themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.20, Briefing.com reports. Editas Medicine had a negative net margin of 960.70% and a negative return on equity of 56.20%. The business had revenue of $2.89 million […]
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Editas Medicine (NASDAQ:EDIT – Get Free Report) had its price target reduced by equities researchers at Chardan Capital from $22.00 to $19.00 in a report released on Wednesday, FlyOnTheWall reports. Chardan Capital’s price target points to a potential upside of 107.88% from the company’s previous close. Several other research firms also recently weighed in on […]
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have been given an average rating of “Hold” by the fourteen research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have assigned a buy recommendation to […]